Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Controlled Trial of ProstAtak® as Adjuvant to Up-front Radiation Therapy For Localized Prostate Cancer

NCT01436968 is registered in ClinicalTrials.gov with Candel Therapeutics, Inc. as lead sponsor.

NCT NCT01436968
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01436968 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Controlled Trial of ProstAtak® as Adjuvant to Up-front Radiation Therapy For Localized Prostate Cancer
Lead sponsor
Candel Therapeutics, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
September 30, 2011
Completion date
December 31, 2030
Enrollment
711 (estimated)
Sites
73

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer